Short answer
Syndax Pharmaceuticals Inc (SNDX) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 text contains only incorporation-by-reference and liability disclaimers.
Syndax Pharmaceuticals Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 text contains only incorporation-by-reference and liability disclaimers
- No operating results, financial figures, reporting period, or investor-impacting disclosures included
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $72.8M, up 92% year over year, driven by Revuforj product revenue $54.7M and Niktimvo collaboration revenue $18.1M
- Revuforj prescriptions approximately 1,500, up 121% year over year, supporting continued menin-inhibitor demand and longer treatment duration
- Niktimvo net revenue $60.3M, up 67% year over year, with Syndax’s profit-share contribution rising 9% sequentially to $18.1M
- Cash, equivalents, and investments $575.1M; 2026 operating-expense guidance approximately $400M excluding $50M stock compensation
- Key catalysts: axatilimab IPF and frontline cGVHD data expected in 4Q26, alongside expanded EGFR and myelofibrosis pipeline development
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Syndax Pharmaceuticals Inc 8-K filings
Get the next SNDX 8-K as it lands
Follow SNDX for push alerts, or ask the research agent what this filing means.